-
Something wrong with this record ?
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
H. Ludwig, M. Boccadoro, P. Moreau, J. San-Miguel, M. Cavo, C. Pawlyn, S. Zweegman, T. Facon, C. Driessen, R. Hajek, MA. Dimopoulos, F. Gay, H. Avet-Loiseau, E. Terpos, N. Zojer, M. Mohty, MV. Mateos, H. Einsele, M. Delforge, J. Caers, K. Weisel,...
Language English Country Great Britain
Document type Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review
NLK
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Nursing & Allied Health Database (ProQuest)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2000-01-01 to 1 year ago
- MeSH
- Immunosuppressive Agents administration & dosage adverse effects therapeutic use MeSH
- Communicable Diseases etiology MeSH
- Clinical Trials as Topic MeSH
- Consensus MeSH
- Communicable Disease Control * MeSH
- Humans MeSH
- Multiple Myeloma complications immunology therapy MeSH
- Practice Guidelines as Topic * MeSH
- Vaccination * MeSH
- Vaccines administration & dosage MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Meta-Analysis MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Geographicals
- Europe MeSH
Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-inherent immune suppression, and because of the immune suppressive effects of therapy. Hence, all appropriate measures should be exploited, to elicit an effective immune response to common pathogens like influenza, pneumococci, varicella zoster virus, and to those bacteria and viruses (haemophilus influenzae, meningococci, and hepatitis) that frequently may pose a significant risk to patients with multiple myeloma. Patients after autologous, and specifically after allogeneic transplantation have severely reduced antibody titers, and therefore require a broader spectrum of vaccinations. Response to vaccination in myeloma often is less vigorous than in the general population, mandating either measurement of the postvaccination antibody titers and/or repeating the vaccination. Here, we compile the existing data on vaccination in multiple myeloma and provide recommendations for clinical practice.
2 Medizinische Klinik und Poliklinik Universitätsklinikum Hamburg Eppendorf Hamburg Germany
CIMA IDISNA CIBERONC Clínica Universidad de Navarra Pamplona Spain
Department of Clinical Hematology CHU of Liège Liège Belgium
Department of Hematology Amsterdam UMC VU University Amsterdam The Netherlands
Department of Hematology Ankara University Ankara Turkey
Department of Hematology Odense University Hospital University of Southern Denmark Odense Denmark
Department of Hematology UZ Leuven Leuven Belgium
Department of Internal Medicine 2 University Hospital Würzburg Würzburg Germany
Department of Medical Oncology and Hematology Cantonal Hospital St Gallen St Gallen Switzerland
Erasmus MC Cancer Institute Erasmus University of Rotterdam Rotterdam The Netherlands
Hôpital Claude Huriez Lille University Hospital Lille France
IBSAL Cancer Research Center University Hospital of Salamanca Salamanca Spain
Interdisciplinary Tumor Center Faculty of Freiburg University of Freiburg Freiburg Germany
NCCC Newcastle upon Tyne Hospitals Trust Newcastle upon Tyne UK
Poitiers University Hospital Poitiers France
Seràgnoli Institute of Hematology Bologna University School of Medicine Bologna Italy
Service hematologie et thérapie cellulaire PRC cic 1402 Inserm CHU poitiers Poitiers France
The Institute of Cancer Research London UK
Unité de Génomique du Myélome University of Toulouse Toulouse France
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21011674
- 003
- CZ-PrNML
- 005
- 20240528153032.0
- 007
- ta
- 008
- 210420s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-020-01016-0 $2 doi
- 035 __
- $a (PubMed)32814840
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Ludwig, Heinz $u Wilhelminen Cancer Research Institute, c/o 1st Department of Medicine, Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring, Vienna, Austria. heinz.ludwig@extern.gesundheitsverbund.at
- 245 10
- $a Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network / $c H. Ludwig, M. Boccadoro, P. Moreau, J. San-Miguel, M. Cavo, C. Pawlyn, S. Zweegman, T. Facon, C. Driessen, R. Hajek, MA. Dimopoulos, F. Gay, H. Avet-Loiseau, E. Terpos, N. Zojer, M. Mohty, MV. Mateos, H. Einsele, M. Delforge, J. Caers, K. Weisel, G. Jackson, L. Garderet, M. Engelhardt, N. van de Donk, X. Leleu, H. Goldschmidt, M. Beksac, I. Nijhof, N. Abildgaard, S. Bringhen, P. Sonneveld
- 520 9_
- $a Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-inherent immune suppression, and because of the immune suppressive effects of therapy. Hence, all appropriate measures should be exploited, to elicit an effective immune response to common pathogens like influenza, pneumococci, varicella zoster virus, and to those bacteria and viruses (haemophilus influenzae, meningococci, and hepatitis) that frequently may pose a significant risk to patients with multiple myeloma. Patients after autologous, and specifically after allogeneic transplantation have severely reduced antibody titers, and therefore require a broader spectrum of vaccinations. Response to vaccination in myeloma often is less vigorous than in the general population, mandating either measurement of the postvaccination antibody titers and/or repeating the vaccination. Here, we compile the existing data on vaccination in multiple myeloma and provide recommendations for clinical practice.
- 650 _2
- $a klinické zkoušky jako téma $7 D002986
- 650 12
- $a kontrola infekčních nemocí $7 D003140
- 650 _2
- $a infekční nemoci $x etiologie $7 D003141
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunosupresiva $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D007166
- 650 _2
- $a mnohočetný myelom $x komplikace $x imunologie $x terapie $7 D009101
- 650 12
- $a směrnice pro lékařskou praxi jako téma $7 D017410
- 650 12
- $a vakcinace $7 D014611
- 650 _2
- $a vakcíny $x aplikace a dávkování $7 D014612
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Boccadoro, Mario $u Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy
- 700 1_
- $a Moreau, Philippe $u Service hematologie et thérapie cellulaire, PRC. cic 1402 Inserm, CHU poitiers, Poitiers, France
- 700 1_
- $a San-Miguel, Jesus $u CIMA, IDISNA, CIBERONC, Clínica Universidad de Navarra, Pamplona, Spain
- 700 1_
- $a Cavo, Michele $u Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
- 700 1_
- $a Pawlyn, Charlotte $u The Institute of Cancer Research, London, UK
- 700 1_
- $a Zweegman, Sonja $u Department of Hematology, Amsterdam UMC, VU University, Amsterdam, The Netherlands
- 700 1_
- $a Facon, Thierry $u Hôpital Claude Huriez, Lille University Hospital, Lille, France
- 700 1_
- $a Driessen, Christoph $u Department of Medical Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland
- 700 1_
- $a Hajek, Roman $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Dimopoulos, Melitios A $u Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Gay, Francesca $u Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy
- 700 1_
- $a Avet-Loiseau, Hervé $u Unité de Génomique du Myélome, University of Toulouse, Toulouse, France
- 700 1_
- $a Terpos, Evangelos $u Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Zojer, Niklas $u 1st Department of Medicine, Center for Hematology, Oncology, and Palliatic Care, Clinic Ottakring, Vienna, Austria
- 700 1_
- $a Mohty, Mohamad $u Department of Clinical Hematology and Cellular Therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France $7 xx0317729
- 700 1_
- $a Mateos, Maria-Victoria $u IBSAL, Cancer Research Center, University Hospital of Salamanca, Salamanca, Spain
- 700 1_
- $a Einsele, Hermann $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
- 700 1_
- $a Delforge, Michel $u Department of Hematology, UZ Leuven, Leuven, Belgium
- 700 1_
- $a Caers, Jo $u Department of Clinical Hematology, CHU of Liège, Liège, Belgium
- 700 1_
- $a Weisel, Katja $u II. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Jackson, Graham $u NCCC, Newcastle upon Tyne Hospitals Trust, Newcastle upon Tyne, UK
- 700 1_
- $a Garderet, Laurent $u INSERM, UMR_S 938, Centre de Recherche Saint-Antoine-Team Proliferation and Differentiation of Stem Cells, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpêtrière, Service d'Hématologie, Sorbonne Université, Paris, France
- 700 1_
- $a Engelhardt, Monika $u Interdisciplinary Tumor Center, Faculty of Freiburg, University of Freiburg, Freiburg, Germany
- 700 1_
- $a van de Donk, Niels $u Department of Hematology, Amsterdam UMC, VU University, Amsterdam, The Netherlands
- 700 1_
- $a Leleu, Xavier $u Poitiers University Hospital, Poitiers, France
- 700 1_
- $a Goldschmidt, Hartmut $u Internal Medicine V and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
- 700 1_
- $a Beksac, Meral $u Department of Hematology, Ankara University, Ankara, Turkey
- 700 1_
- $a Nijhof, Inger $u Department of Hematology, Amsterdam UMC, VU University, Amsterdam, The Netherlands
- 700 1_
- $a Abildgaard, Niels $u Department of Hematology, Odense University Hospital, University of Southern Denmark, Odense, Denmark
- 700 1_
- $a Bringhen, Sara $u Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy
- 700 1_
- $a Sonneveld, Pieter $u Erasmus MC Cancer Institute, Erasmus University of Rotterdam, Rotterdam, The Netherlands
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 35, č. 1 (2021), s. 31-44
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32814840 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20240528153029 $b ABA008
- 999 __
- $a ok $b bmc $g 1650138 $s 1132053
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 35 $c 1 $d 31-44 $e 20200819 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20210420
